Group 1 - The forum "Technology Transfer Future: Technology and Industry Breakthrough Forum" was held at Fudan University, focusing on topics such as "industrialization of scientific achievements," "hard technology breakthrough paths," and "collaborative innovation ecosystem" [1] - Fudan University's Zhangjiang campus is becoming a key platform for deep integration of technology and finance, emphasizing the importance of financial support for both basic research and market demand [1] - The Master of Technology Transfer (MTT) program aims to cultivate interdisciplinary talents who understand technology, finance, and management, addressing the talent gap in the technology transfer ecosystem [1] Group 2 - The MTT program is built on Fudan University's top disciplines in finance, engineering, medicine, and law, closely aligning with industry needs through a dual-track training system of "systematic courses + in-depth practice" [2] - The program focuses on five major industries: artificial intelligence, biomedicine, integrated circuits, new energy and new materials, and aerospace technology, promoting the commercialization of technology [2] - A roundtable discussion was held on "resource collaboration and institutional breakthroughs in the technology transfer ecosystem," led by the MTT program director [2] Group 3 - Fudan University's Technology Transfer Center is actively exploring practices in the field of technology transfer, including progress in intellectual property management and empowerment reforms [3] - The center is building a "technology + industry + investment" communication platform to match research technology with industrial transformation needs, fostering a conducive ecosystem for technology transfer [3] - The center has successfully facilitated multiple projects in biomedicine, integrated circuits, artificial intelligence, new materials, and medical engineering, achieving several successful technology transfers [3]

Core Viewpoint - Junshi Bioscience has shown significant stock price appreciation in 2023, with a year-to-date increase of 73.14% and notable gains over various trading periods [2]. Group 1: Stock Performance - As of September 3, Junshi Bioscience's stock price reached 47.32 CNY per share, with a market capitalization of 48.583 billion CNY [1]. - The stock has increased by 9.08% over the last 5 trading days, 14.63% over the last 20 days, and 29.22% over the last 60 days [2]. Group 2: Financial Performance - For the first half of 2025, Junshi Bioscience reported revenue of 1.168 billion CNY, representing a year-on-year growth of 48.64% [2]. - The company recorded a net profit attributable to shareholders of -413 million CNY, which is a 36.01% increase compared to the previous period [2]. Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Junshi Bioscience increased to 31,200, up by 5.88% from the previous period [2]. - The average number of circulating shares per shareholder decreased by 5.56% to 24,543 shares [2]. Group 4: Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include Huaxia SSE STAR 50 ETF, which holds 29.7167 million shares, a decrease of 536,700 shares from the previous period [3]. - E Fund SSE STAR 50 ETF increased its holdings to 22.2132 million shares, an increase of 630,000 shares [3].

Group 1: Company Performance Overview - In the first half of 2025, the company focused on "maintaining some and reducing others, with moderate expansion," leading to a significant improvement in operating cash flow by 57.35% year-on-year, enhancing capital turnover efficiency [2][3] - Revenue for Q2 2025 increased by 24.38% compared to Q1 2025, while the net profit attributable to shareholders reduced losses by 38.10%, indicating a recovery in operational capabilities [3][17] Group 2: Business Strategy and Focus Areas - The company is actively integrating its core business segments, including food, environment, and medical laboratories, while expanding into emerging sectors like biomedicine and medical devices, which have shown promising revenue growth [2][4] - The long-term goal is to achieve a balanced revenue structure with a 50:50 ratio between chemical and physical testing services, while continuing to deepen traditional sectors like food and environmental testing [4][15] Group 3: Accounts Receivable Management - The company has strengthened accounts receivable management through enhanced credit control and optimized customer structure, implementing tailored collection strategies for major clients to ensure efficient debt recovery [2][3] Group 4: Market Outlook and Growth Opportunities - The company is optimistic about the growth of its biomedicine sector, leveraging its professional capabilities to maintain competitive pricing and increasing order volumes from well-known pharmaceutical companies [4][15] - Plans for overseas expansion are in the pipeline, with a focus on sectors such as electronics, medical devices, food, and automotive, considering acquisitions as a primary mode of entry [6][17] Group 5: Sector-Specific Insights - In the automotive testing sector, the company has achieved an 80% capacity utilization rate, with plans for upgrades to further enhance efficiency and profitability [7][17] - The elevator testing business is expected to maintain sustainability due to regular inspection demands and the growing number of elevators in operation [8][12] Group 6: Future Initiatives and Challenges - The company aims to capitalize on the upcoming business peak in the second half of 2025 by enhancing its overall competitiveness and focusing on high-demand sectors such as biomedicine, medical devices, and special equipment [10][17] - Traditional sectors like food safety and environmental testing will continue to be prioritized, with ongoing commitments to national safety standards and environmental monitoring initiatives [10][12]

Company Overview - 博瑞医药 (Borui Pharmaceutical) is located in Suzhou Industrial Park, Jiangsu Province, and was established on October 26, 2001. The company went public on November 8, 2019. Its main business involves the research and production of high-end generic drugs and original new drugs [1]. Stock Performance - As of September 3, the stock price of 博瑞医药 was 89.41 CNY per share, with a market capitalization of 37.8 billion CNY. The stock has increased by 197% year-to-date but has seen a decline of 14.85% over the last five trading days and 21.57% over the last 20 days [1]. - The trading volume on September 3 was 605 million CNY, with a turnover rate of 1.57% [1]. Financial Performance - For the first half of 2025, 博瑞医药 reported a revenue of 537 million CNY, a year-on-year decrease of 18.28%. The net profit attributable to shareholders was 17.17 million CNY, down 83.85% year-on-year [2]. - Cumulative cash dividends since the A-share listing amount to 246 million CNY, with 129 million CNY distributed over the past three years [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders was 9,568, a decrease of 10.11% from the previous period. The average number of circulating shares per person increased by 11.32% to 44,185 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 3.25 million shares, a decrease of 1.06 million shares from the previous period. 新进股东 (Innovation Drug) is the tenth largest shareholder with 2.81 million shares [3].

Core Viewpoint - Bid Pharma's stock price has shown significant growth this year, with a 42.80% increase, indicating strong market performance and investor interest [1][2]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the first half of 2025, Bid Pharma achieved a revenue of 628 million yuan, representing a year-on-year growth of 17.91%. The net profit attributable to shareholders was 73.41 million yuan, reflecting a 41.60% increase compared to the previous year [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 4.76% to 3,782, while the average circulating shares per person decreased by 4.55% to 11,431 shares [2]. - Notable changes in institutional holdings include a decrease in shares held by China Europe Medical Health Mixed A and an increase in shares held by Agricultural Bank of China Medical Health Stock [3].

Company Overview - Changchun High-tech Industry (Group) Co., Ltd. is located in Changchun, Jilin Province, and was established on June 10, 1993. It was listed on December 18, 1996. The company primarily engages in the research, production, and sales of biopharmaceuticals and traditional Chinese medicine, along with real estate development and property management services. The revenue composition is as follows: pharmaceuticals 92.83%, real estate 6.81%, and services 0.36% [1]. Stock Performance - As of September 3, Changchun High-tech's stock price decreased by 2.01%, trading at 122.20 CNY per share, with a total transaction volume of 1.758 billion CNY and a turnover rate of 3.53%. The total market capitalization is 49.85 billion CNY [1]. - Year-to-date, the stock price has increased by 26.14%, with a 19.44% rise over the last five trading days, 17.73% over the last 20 days, and 19.43% over the last 60 days [1]. Capital Flow - In terms of capital flow, there was a net outflow of 151 million CNY from main funds, with large orders buying 420 million CNY (23.87%) and selling 466 million CNY (26.51%). Special large orders bought 302 million CNY (17.16%) and sold 407 million CNY (23.14%) [1]. Financial Performance - For the first half of 2025, Changchun High-tech reported a revenue of 6.603 billion CNY, a year-on-year decrease of 0.54%. The net profit attributable to shareholders was 983 million CNY, down 42.85% year-on-year [2]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 12.78% to 109,100, with an average of 3,662 shares per shareholder, an increase of 14.66% [2]. - The company has distributed a total of 4.791 billion CNY in dividends since its A-share listing, with 3.259 billion CNY distributed in the last three years [3]. Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited as the third-largest shareholder with 8.4381 million shares (a decrease of 3.4502 million shares), and Huatai-PB CSI 300 ETF as the fifth-largest with 5.7621 million shares (an increase of 731,600 shares) [3].

Company Overview - Huadong Medicine Co., Ltd. is located in Hangzhou, Zhejiang Province, and was established on March 31, 1993, with its listing date on January 27, 2000. The company primarily engages in the production and sales of various pharmaceutical products, including Bailing capsules, New Saisping (oral liquid, soft capsules), Palisou, and Carboplatin, as well as pharmaceutical wholesale [1][2]. Financial Performance - As of June 30, 2025, Huadong Medicine achieved a revenue of 21.675 billion yuan, representing a year-on-year growth of 3.39%. The net profit attributable to shareholders was 1.815 billion yuan, reflecting a year-on-year increase of 7.01% [2]. - The company has cumulatively distributed dividends of 8.259 billion yuan since its A-share listing, with 3.158 billion yuan distributed over the past three years [3]. Stock Performance - On September 3, Huadong Medicine's stock price increased by 2.03%, reaching 45.73 yuan per share, with a trading volume of 159 million yuan and a turnover rate of 0.20%. The total market capitalization stood at 80.214 billion yuan [1]. - Year-to-date, the stock price has risen by 34.42%, with a 3.30% increase over the last five trading days, a 3.93% increase over the last 20 days, and a 5.37% increase over the last 60 days [1]. Shareholder Structure - As of June 30, 2025, the number of Huadong Medicine's shareholders was 69,800, a decrease of 7.91% from the previous period. The average number of circulating shares per person increased by 8.59% to 25,083 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 39.8384 million shares, a decrease of 6.2825 million shares from the previous period. Other notable shareholders include China Europe Medical Health Mixed A and Huatai-PineBridge CSI 300 ETF, with varying changes in their holdings [3].

Market Performance - On September 2, the Shanghai Composite Index fell by 0.45%, the Shenzhen Component Index dropped by 2.14%, and the ChiNext Index decreased by 2.85%[3] - The total trading volume on September 2 was 2.91 trillion, an increase of approximately 130 billion compared to the previous trading day[1] Sector Analysis - Major sectors experienced declines, with communication, computing, electronics, and military industries leading the losses, while banking, utilities, and home appliances saw slight gains[1] - The net outflow of funds from the Shanghai market was 194.51 billion yuan, and from the Shenzhen market, it was 315.77 billion yuan on September 2[4] Market Sentiment - The market is facing significant resistance at its current position, with a more pronounced adjustment compared to the previous trading days[1] - There is a short-term pressure for profit-taking in the main sectors, leading to increased volatility in market sentiment[1] Industry Developments - The logistics industry in China showed a positive trend with a logistics prosperity index of 50.9% in August, indicating continuous demand growth[7] - The software industry reported a revenue of 83,246 billion yuan in the first seven months of the year, reflecting a year-on-year growth of 12.3%[8] Investment Trends - Overseas Chinese stock ETFs have seen significant growth, with the KraneShares China Internet ETF surpassing 8.5 billion USD in size[11] - Recent policies in Shanghai support the development of AI chips, indicating a focus on enhancing technological capabilities in the region[5][6]

本报讯(记者徐冠英张宣)2025江苏产学研合作对接大会将于9月11日在南京国际展览中心开幕。此次大 会将发布江苏近3年200余项产业科技创新标志性成果，呈现江苏在人工智能、生物医药、集成电路、新 能源、新材料、低空经济、深海深空深地等领域的创新突破。 江苏已连续两年在9月11日举办产学研合作对接大会，推动创新侧和产业端对接合作，不仅成果丰硕， 也产生广泛影响。今年大会已邀请到180多位国内外高层次专家，包括50多位两院院士、70多位省内外 高校院所领导，参会的国内外知名高校院所达到100余家。 作为促进科技成果转化应用的重要平台，本次大会更加注重"对接"——发布4100多项高校院所科技成 果、3600多项企业技术需求，并首次设置3000多平方米的超大规模对接洽谈区，组织4000多家企业与专 家教授、技术经理人、金融机构等开展线下洽谈。 为推动高校院所的硬成果与科技企业的真需求高效"碰撞"，大会设置4个专场活动：重大科技成果发布 对接专场，邀请中国科学院系统研究院所发布最新科技成果、科技部新质生产力促进中心发布国家科技 计划主导形成的重大科研成果，组织江苏企业与科研团队对接洽谈；高新区新质转型行动暨"双高协 同 ...

二是打造特色金融服务品牌IP"科技金融汇客厅"，截至目前已围绕生物医药、人工智能、跨境贸易、知 识产权等主题举办十一场对接活动，累计吸引超百家金融机构、千余家实体企业参与，共同探索金融和 产业融合发展的新路径、新模式，有效拓宽企业融资渠道，加速产融深度结合。 三是在优化金融服务方面，郑州航空港已提格升级管理，基金注册会商工作直通省直，基金管理人注册 由省区两级会商，基金产品区级会商即可完成注册，大大缩短了注册流程、节约了时间。同时，郑州航 空港建立了综合金融服务平台，由国有平台公司的专业团队提供包括资料辅导、工商办理、办公入驻等 一站式免费金融服务，为投资机构"入港"提供了便利优越的环境。 该负责人介绍，为推动创业投资企业在港区集聚发展，郑州航空港从政策、平台、服务等多方面发力， 实施了一系列有力举措： 一是通过政策组合拳激活创投动能，以制度创新鼓励机构加大风险投资力度。2025年3月，郑州航空港 印发了《郑州航空港经济综合实验区国有投资基金容错尽职免责管理办法》，在省内率先打破"唯成功 论"桎梏，明确对投小投早投硬科技领域的合理失败予以容错免责，既为国有资本参与高风险科创投资 卸下"包袱"，也为社会资本树立 ...